VARIVAX - A newly approved by the FDA a live-varicella virus vaccine. Limited clinical trials suggest the immunity lasts for at least six years. The only significant adverse reaction detected in clinical studies was pain and redness at the injection site. Children (or adults) with a history for an anaphylactoid reaction to neomycin or gelatin, or the presence of any febrile illness, should not be given the vaccine. Pregnant women and those who are immunocompromised should also not receive the vaccine. It is furthermore recommended that pregnancy be avoided for 3 months following vaccination. One 0.5 cc injection of Varivax is recommended for children aged 12 months to 12 years and two 0.5 cc injections 4 to 8 weeks apart are recommended for patients 13 years and older. In trials involving 9,000 children, 80% were protected and 20% reported mild cases.